Assessment of the ultrastructural and proliferative properties of human embryonic stem cell-derived cardiomyocytes
- PMID: 14613910
- DOI: 10.1152/ajpheart.00020.2003
Assessment of the ultrastructural and proliferative properties of human embryonic stem cell-derived cardiomyocytes
Abstract
Assessment of early ultrastructural development and cell-cycle regulation in human cardiac tissue is significantly hampered by the lack of a suitable in vitro model. Here we describe the possible utilization of human embryonic stem cell (ES) lines for investigation of these processes. With the use of the embryoid body (EB) differentiation system, human ES cell-derived cardiomyocytes at different developmental stages were isolated and their histomorphometric, ultrastructural, and proliferative properties were characterized. Histomorphometric analysis revealed an increase in cell length, area, and length-to-width ratio in late-stage EBs (>35 days) compared with early (10-21 days) and intermediate (21-35 days) stages. This was coupled with a progressive ultrastructural development from an irregular myofibrillar distribution to an organized sarcomeric pattern. Cardiomyocyte proliferation, assessed by double labeling with cardiac-specific antibodies and either [3H]thymidine incorporation or Ki-67 immunolabeling, demonstrated a gradual withdrawal from cell cycle. Hence, the percentage of positively stained nuclei in early-stage cardiomyocytes ([3H]thymidine: 60 +/- 10%, Ki-67: 54 +/- 23%) decreased to 36 +/- 7% and 9 +/- 16% in intermediate-stage EBs and to <1% in late-stage cardiomyocytes. In conclusion, a reproducible temporal pattern of early cardiomyocyte proliferation, cell-cycle withdrawal, and ultrastructural maturation was noted in this model. Establishment of this unique in vitro surrogate system may allow to examine the molecular mechanisms underlying these processes and to assess interventions aiming to modify these properties. Moreover, the detailed characterization of the ES cell-derived cardiomyocyte may be crucial for the development of future cell replacement strategies aiming to regenerate functional myocardium.
Similar articles
-
Human embryonic stem cells can differentiate into myocytes with structural and functional properties of cardiomyocytes.J Clin Invest. 2001 Aug;108(3):407-14. doi: 10.1172/JCI12131. J Clin Invest. 2001. PMID: 11489934 Free PMC article.
-
Scalable producing embryoid bodies by rotary cell culture system and constructing engineered cardiac tissue with ES-derived cardiomyocytes in vitro.Biotechnol Prog. 2006 May-Jun;22(3):811-8. doi: 10.1021/bp060018z. Biotechnol Prog. 2006. PMID: 16739965
-
DNA synthesis and multinucleation in embryonic stem cell-derived cardiomyocytes.Am J Physiol. 1995 Dec;269(6 Pt 2):H1913-21. doi: 10.1152/ajpheart.1995.269.6.H1913. Am J Physiol. 1995. PMID: 8594899
-
Derivation and potential applications of human embryonic stem cells.Circ Res. 2002 Nov 15;91(10):866-76. doi: 10.1161/01.res.0000041435.95082.84. Circ Res. 2002. PMID: 12433831 Review.
-
Embryonic stem cells and cardiomyocyte differentiation: phenotypic and molecular analyses.J Cell Mol Med. 2005 Oct-Dec;9(4):804-17. doi: 10.1111/j.1582-4934.2005.tb00381.x. J Cell Mol Med. 2005. PMID: 16364192 Free PMC article. Review.
Cited by
-
Recapitulating Cardiac Structure and Function In Vitro from Simple to Complex Engineering.Micromachines (Basel). 2021 Apr 1;12(4):386. doi: 10.3390/mi12040386. Micromachines (Basel). 2021. PMID: 33916254 Free PMC article. Review.
-
Cardiovascular Disease Modeling Using Patient-Specific Induced Pluripotent Stem Cells.Int J Mol Sci. 2015 Aug 12;16(8):18894-922. doi: 10.3390/ijms160818894. Int J Mol Sci. 2015. PMID: 26274955 Free PMC article. Review.
-
miR-25 Promotes Cardiomyocyte Proliferation by Targeting FBXW7.Mol Ther Nucleic Acids. 2020 Mar 6;19:1299-1308. doi: 10.1016/j.omtn.2020.01.013. Epub 2020 Jan 21. Mol Ther Nucleic Acids. 2020. PMID: 32160702 Free PMC article.
-
Engineering Scalable Manufacturing of High-Quality Stem Cell-Derived Cardiomyocytes for Cardiac Tissue Repair.Front Med (Lausanne). 2018 Apr 24;5:110. doi: 10.3389/fmed.2018.00110. eCollection 2018. Front Med (Lausanne). 2018. PMID: 29740580 Free PMC article. Review.
-
Thinking Outside the Heart: Use of Engineered Cardiac Tissue for the Treatment of Chronic Deep Venous Insufficiency.J Cardiovasc Pharmacol Ther. 2014 Jul;19(4):394-401. doi: 10.1177/1074248413520343. Epub 2014 Feb 4. J Cardiovasc Pharmacol Ther. 2014. PMID: 24500906 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical